# US 2026/0089162 A1 · Diabetes management partner interface for wireless communication of analyte data > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0089162 A1 - Document ID: US20260089162A1 - Status: Published application - Kind: A1 - Application number: 19/409,595 - Filed: 2025-12-04 - Published: 2026-03-26 - Earliest claimed: 2017-10-30 - Assignees: DexCom, Inc. - Applicants: Dexcom, Inc. - Inventors: Apurv Ullas KAMATH; Michael Robert MENSINGER; Nicholas POLYTARIDIS; Gary A. MORRIS; Alexandra Elena CONSTANTIN; Douglas William BURNETTE; Mario REMON; Jorge R. BARRERAS; Benjamin Elrod WEST; Christopher Robert HANNEMANN - Web page: https://patentgrep.com/patent/US20260089162A1 ## CPC - H04L 63/101: {Access control lists [ACL]} - A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement} - A61B 5/686: {Permanently implanted devices, e.g. pacemakers, other stimulators, biochips (A61B5/6861 takes precedence)} - G16H 10/60: for patient-specific data, e.g. for electronic patient records - G16H 10/65: stored on portable record carriers, e.g. on smartcards, RFID tags or CD - G16H 20/17: delivered via infusion or injection - G16H 40/40: for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades - G16H 40/63: for local operation - G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems - H04W 12/06: Authentication - H04W 52/0277: {according to available power supply, e.g. switching off when a low battery condition is detected} - H04W 76/14: Direct-mode setup - A61B 5/0002: {Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network (endoradiosondes A61B5/07)} - A61B 5/0004: {characterised by the type of physiological signal transmitted} - A61B 5/14503: {invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors (A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence)} - A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes} - A61B 5/1495: Calibrating or testing of in-vivo probes - A61B 5/486: {Biofeedback (using electroencephalography [EEG] A61B5/375)} - A61B 5/7445: {Display arrangements, e.g. multiple display units} - A61B 5/746: {Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms} - H04L 2209/88: Medical equipments - H04W 4/38: for collecting sensor information - H04W 4/80: Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication - Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation - Y02D 30/70: in wireless communication networks - H04L: TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION (arrangements common to telegraphic and telephonic communication H04M) - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA - H04W: WIRELESS COMMUNICATION NETWORKS (broadcast communication H04H; communication systems using wireless links for non-selective communication, e.g. wireless extensions H04M1/72) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE - Y02D: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN INFORMATION AND COMMUNICATION TECHNOLOGIES [ICT], I.E. INFORMATION AND COMMUNICATION TECHNOLOGIES AIMING AT THE REDUCTION OF THEIR OWN ENERGY USE ## Abstract Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device. ## Claims ### Claim 1 A system for providing information regarding analyte values in a user's body, comprising a display device in wireless communication with an analyte sensor system and a partner device, wherein the partner device is an insulin delivery device, and wherein the partner device is not directly connected to the analyte sensor system, wherein: the display device is configured to receive analyte data from the analyte sensor system; the partner device is configured to deliver insulin to a user based on analyte data generated using the analyte sensor system, or data derived therefrom, that is received from the display device; the display device is configured to alert the user and provide analyte data received from the analyte sensor system; the display device is configured to provide information relating to delivery of insulin by the partner device; the display device is configured to communicate with the analyte sensor system using a wireless connection model which involves the display device performing an initial pairing with the analyte sensor system, after which the display device remains connected to the analyte sensor system for communication; the display device is configured to receive medicament-related data from the insulin delivery device and provide the medicament-related data to the user; and the display device is configured to receive the medicament-related data periodically from the insulin delivery device using a wireless model in which the display device and the insulin delivery device wirelessly communicate. ### Claim 2 (depends on 1) The system of claim 1, wherein the display device is configured to: store volumes of analyte-related data received from analyte sensor system and volumes of medicament-related data received from the insulin delivery device; and receive input and allow a user to interact with the analyte-related data and medicament-related data via a graphical user interface of the display device. ### Claim 3 (depends on 1) The system of claim 1, wherein the display device is configured to trigger alerts based on events or conditions detected at the insulin delivery device. ### Claim 4 (depends on 3) The system of claim 3, wherein the display device is configured to trigger an alert if the display device determines that the insulin delivery device has a mechanical or other failure. ### Claim 5 (depends on 1) The system of claim 1, wherein the display device is configured to trigger an alert based on characteristics of the analyte data generated using the analyte sensor system. ### Claim 6 (depends on 5) The system of claim 5, wherein the alert is a hypoglycemic alert that is triggered based on alert conditions indicating a minimum glucose level or based on alert conditions indicating a minimum required trend is present in the a glucose level of the user. ### Claim 7 (depends on 1) The system of claim 1, wherein, in order to communicate with the analyte sensor system according to the wireless connection model, the display device is configured to: receive advertisement messages transmitted by the analyte sensor system; establish a connection with the analyte sensor system; periodically exchange data with the analyte sensor system; and periodically exchange ping messages with the analyte sensor system to maintain the connection. ### Claim 8 (depends on 1) The system of claim 1, wherein, upon the display device becoming disconnected from the analyte sensor system, display device is configured to provide a notification to the user that the connection has been lost. ### Claim 9 (depends on 1) The system of claim 1, wherein the system is configured to utilize a wide area network (WAN) to provide at least one of analyte information, medicament delivery information or information related to use of the insulin delivery device to an electronic device of a follower of the user of the analyte sensor system. ### Claim 10 (depends on 9) The system of claim 9, wherein the electronic device of the follower runs an application specifically designed for following the user. ### Claim 11 (depends on 10) The system of claim 10, wherein the application on the electronic device of the follower is configured to provide one or more of alerts, insulin values, insulin visualization and continuous glucose monitoring (CGM) values. ### Claim 12 (depends on 9) The system of claim 9, wherein the analyte information is glucose data and the medicament delivery information is insulin data. ### Claim 13 (depends on 1) The system of claim 1, wherein the partner device is configured to deliver the insulin to a user based on analyte data generated using the analyte sensor system, or data derived therefrom by delivering a bolus of insulin to the user based on one or more bolus calculation parameters. ### Claim 14 (depends on 13) The system of claim 13, wherein the partner device is provided access to the one or more bolus calculation parameters. ### Claim 15 (depends on 1) The system of claim 1, wherein the display device is configured to receive the medicament-related data from the insulin delivery device and provide the medicament-related data to the user via one or more applications stored on the display device. ### Claim 16 (depends on 15) The system of claim 15, wherein the one or more applications comprise one or more of an analyte sensor application, a partner device application and a medicament delivery application. ### Claim 17 (depends on 16) The system of claim 16, wherein the one of more applications are linked together, or merged into a single application.